Table 3.

Pharmacokinetic parameters of 5-FU in 115 colorectal cancer patients after the first dose of 5-FU in adjuvant chemotherapy

Disease recurrence at 5 y of follow-upNo, n = 57 patients (median)Yes, n = 58 patients (median)
Daily dose (mg)615 ± 79 (602)629 ± 94 (614)
DPD (pmol/min/mg)196.1 ± 125.9 (163.3)179.0 ± 105.2 (164.9)
5-FU
AUC (h × mg/L)9.3 ± 4.1 (8.5)*7.5 ± 2.9 (6.8)
CL (L/h/m2)48.0 ± 22.4 (43.6)57.5 ± 25.7 (54.1)
Vd (L/m2)17.3 ± 15.8 (13.2)19.4 ± 15.3 (13.8)
t1/2 (h)0.25 ± 0.20 (0.20)0.25 ± 0.18 (0.21)
Cmax (mg/L)21.8 ± 16.3 (18.0)21.0 ± 14.6 (17.6)
5-FDHU
AUC (h × mg/L)11.0 ± 4.7 (10.8)11.8 ± 9.9 (9.5)
t1/2 (h)1.02 ± 1.20 (0.65)1.07 ± 1.95 (0.52)
Cmax (mg/L)4.7 ± 1.5 (4.4)4.8 ± 1.3 (4.5)
Tmax (h)0.74 ± 0.22 (0.75)0.67 ± 0.20 (0.67)
AUC ratio0.96 ± 0.57 (0.82)0.76 ± 0.35 (0.64)
  • NOTE: Patients were divided in two groups according to their 5-y follow-up.

  • * Significantly different from patients who experienced diseases recurrence (unpaired t-test with Welch's correction).